A5083682379- Sarcoma Diagnosis and Treatment
- Management of metastatic bone disease
- Lymphoma Diagnosis and Treatment
- Immune cells in cancer
- Cancer, Hypoxia, and Metabolism
- Peptidase Inhibition and Analysis
- Lung Cancer Treatments and Mutations
- Ferroptosis and cancer prognosis
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Testicular diseases and treatments
- Chromatin Remodeling and Cancer
- Gut microbiota and health
- Diatoms and Algae Research
- Cancer Mechanisms and Therapy
- Circular RNAs in diseases
- interferon and immune responses
- RNA modifications and cancer
- Colorectal and Anal Carcinomas
- Chronic Myeloid Leukemia Treatments
- Glioma Diagnosis and Treatment
- Immune Response and Inflammation
Peking University People's Hospital
2018-2024
Peking University
2018-2024
Qingdao University
2023
Affiliated Hospital of Qingdao University
2023
Daping Hospital
2022
Army Medical University
2022
First Affiliated Hospital of Xi'an Jiaotong University
2021
Beijing Chest Hospital
2018-2020
Capital University
2020
Capital Medical University
2020
Osteosarcoma is one of the most aggressive malignant bone tumors worldwide. Although great advancements have been made in its treatment owing to advent neoadjuvant chemotherapy, problem lung metastasis a major obstacle improvement survival outcomes. Thus, aim present study screen novel and key biomarkers, which may act as potential prognostic markers therapeutic targets osteosarcoma. We utilized Robust Rank Aggregation (RRA) method integrate three osteosarcoma microarray datasets downloaded...
11507 Background: Patients (pts) with relapsed and refractory (R/R) osteosarcoma have a poor prognosis limited therapeutic options. HS-20093 is novel antibody-drug conjugate (ADC) targeting B7-H3, which showed preliminary anti-tumor activity in phase 1 ARTEMIS-001 study (NCT05276609). Here we report results R/R pts treated from ARTEMIS-002 (NCT05830123). Methods: trial an open label, two-arm 2 or other sarcomas progressed upon standard systemic treatment. Based on the of that maximum...
Multi-drug-resistant bacterial infections, which have become a global threat, lack effective treatments. The discoveries of non-antibiotics with different modes antibacterial action, such as methylsulfonylmethane (MSM), are promising new treatment for multi-drug-resistant pathogens.We constructed mouse peritonitis infection model to evaluate the effects MSM against methicillin-resistant Staphylococcus aureus (MRSA) infection. time-kill kinetics MRSA and effect on integrity cell membrane were...
Osteosarcoma is the most common primary malignant bone tumour predominantly occurring in children and adolescents with a high tendency of local invasion early metastases. Currently, immune microenvironment (TME) becoming focus studying tumours.. However, no sound evidence shows specific molecular target osteosarcoma. We downloaded gene expression profile clinical data osteosarcoma from TARGET portal, extracted normalized via R software. Then, cell infiltration assessed by CIBERSORT ESTIMATE...
Abstract Purpose: The optimal dose schedule of vincristine, irinotecan, and temozolomide (VIT) in relapsed or refractory patients with Ewing sarcoma requires clarification. Patients Methods: were randomly assigned (1:1) to either a shorter d × 5 (irinotecan 50 mg/m2/d D1–5, vincristine 1.4 mg/m2 D1) protracted 5×2 20 D1–5,8–12, D1,8) together (100 D1–5). treated every 3 weeks for up eight cycles until progression unacceptable toxic effects occurred. primary endpoint was objective response...
Novel and effective immunotherapies are required for refractory or recurrent sarcomas. Transforming growth factor-beta (TGF-β) is a diverse regulatory fibrogenic protein expressed in multiple sarcoma tumors that promotes epithelial-mesenchymal transition excessive deposition of extracellular matrix. This study evaluated the efficacy safety anti-PD-L1/TGF-β antibody TQB2858 patients with osteosarcoma alveolar soft part (ASPS). single-arm phase 1b exploratory included ASPS who had previously...
Abstract Background Epithelioid sarcoma is a rare soft tissue characterized by SMARCB1/INI1 deficiency. Much attention has been paid to the selective EZH2 inhibitor tazemetostat, where other systemic treatments are generally ignored. To explore alternative treatment options, we studied effects of irinotecan-based chemotherapy in series epithelioid patients. Methods We retrospectively reviewed data from patients with metastatic or unresectable at Peking University People’s Hospital treated...
Objective Multitargeted tyrosine kinase inhibitors (TKIs) have been approved as second‐line therapy in refractory sarcoma, prolonging progression‐free survival (PFS) but with short‐lived duration of disease control. Fruquintinib is a TKI that specifically inhibits vascular endothelial growth factor receptor‐1,2,3 no metabolism by liver enzymes. In this retrospective study, we assessed the efficacy and safety fruquintinib‐based treatment patients sarcoma after developing several lines...
Our research aimed to illuminate the role of miR-100-5p in chordoma and potential mechanism.We used microRNA array analysis explore differentially expressed miRNAs tissue then verified by qRT-PCR. Cell proliferation transwell assay were evaluate function miR-100-5p. apoptosis was analyzed flow cytometry, using biological software, we predicted that insulin-like growth factor 1 receptor (IGF1R) could be target gene miR-100-5p, which validated dual luciferase assays Western blot.miR-100-5p...
For osteosarcoma that progresses following first-line chemotherapy, prognosis remains poor although anti-angiogenesis tyrosine kinase inhibitors (TKIs) have been verified to prolong progression-free survival. Apatinib has led positive responses in the treatment of refractory osteosarcoma. However, it demonstrates only short-lived activity, and disease control rate musculoskeletal lesions is worse compared with pulmonary lesions. This failure partly overcome by addition ifosfamide etoposide...
Breast cancer is the most commonly diagnosed malignancy in women; thus, more prevention research urgently needed. The aim of this study was to predict potential therapeutic agents for breast and determine their molecular mechanisms using integrated bioinformatics. Summary data from a large genome-wide association derived UK Biobank. gene expression profile Oncomine database. We performed network-wide set enrichment analysis identify significant genes cancer. Then, we Gene Ontology STRING...
Objectives The fact that studies on anti‐programmed cell death 1 (PD‐1) or its relevant ligand (PD‐L1) have yielded such few responses greatly decreases the confidence in immunotherapy with checkpoint inhibitors for advanced osteosarcoma. We intended to characterize expression of various molecules immunohistochemistry osteosarcoma specimens and analyzed relationship these patients' clinical courses. Methods This study was a retrospective non‐intervention from August 1st 2017 March 2020....
Objective: To compare the prognosis of patients with cervical cancer in stage Ⅰb2-Ⅱa2 undergoing laparoscopic radical hysterectomy or abdominal hysterectomy. Methods: From January 1, 2009 to December 31, 2018, who underwent (laparoscopic group and group) Peking University People's Hospital were collected. The clinicopathological data retrospectively analyzed. There 237 cases this study, including 115 122 group. characteristics, surgery-related complications, recurrence death analyzed between...
Abstract This study aims to investigate the effects of hyperthermia on intestinal microecology, immune function, and progression-free survival patients with advanced unresectable lung adenocarcinoma. A total twenty adenocarcinoma in group received standard first-line treatment protocol, which included pemetrexed + cisplatin combined sintilimab immunotherapy hyperthermia. Additionally, control immunotherapy. The T-lymphocyte subpopulation CD4/CD8 cell ratio each sample were detected using...
e23502 Background: The effectiveness of eribulin and irinotecan in treatment xenograft models Ewing sarcoma is well-established but little clinical data has been reported. Encouraging results from preclinical a shortage temozolomide our hospital have prompted the administration as substitute for vincristine combination at institution 2022 to 2023 an off-label way. Methods: We retrospectively reviewed medical records patients treated refractory or recurrent with 1.4mg/m 2 D 1,8 20mg/m /d...
11528 Background: Multi-targeted tyrosine kinase inhibitors (TKIs) have been approved as the second-line therapy for refractory bone and soft tissue sarcomas, prolonging progression-free survival (PFS) but with still limited duration of disease control. Fruquintinib is a highly selective TKI that inhibits vascular endothelial growth factor receptor (VEGFR)-1,2,3 without undergoing metabolism by liver enzymes. This retrospective study assessed efficacy safety fruquintinib-based treatment in...
Abstract BackgroundIn the glioma microenvironment, infiltrating immune cells has been shown to possess beneficial effects for tumor progression. Immune and stromal dominate microenvironment in glioma. The complex interplay between progression with or was still unknown. MethodsIn this study, we used Estimation of malignant tissues using expression data (ESTIMATE) calculations calculate proportion tumour-infiltrating (TIC) number components cases from cancer Genome Atlas (TCGA) Chinese Glioma...